A型肉毒杆菌毒素（Ipsen Biopharm Ltd）(AbobotulinumtoxinA (Ipsen Biopharm Ltd)) - 药物靶点：SNAP25_在研适应症：肌肉痉挛，上下肢痉挛，眉间纹_专利_临床

概要

基本信息

药物类型

毒素

别名

Botulinum toxin A (Ipsen)、Botulinum Toxin Type A (Ipsen biopharm Limited)、BTX-A-HAC NG

+ [9]

靶点

SNAP25

作用方式

抑制剂

作用机制

SNAP25 抑制剂(突触相关蛋白25 抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Ipsen SAIpsen Biopharm Ltd.Ipsen Ltd.

非在研机构

Ipsen Innovation SAS

权益机构-

最高研发阶段批准上市

首次获批日期

英国 (2009-01-28),

肌张力失调

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 20749948

关联

91

项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的临床试验

NCT07427797

/ Recruiting临床3期

A Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Single Dose of IPN10200 in the Improvement of Moderate to Severe Glabellar Lines in Adult Participants

The purpose of this study is to assess the effectiveness and safety of IPN10200 compared to placebo in the improvement of the appearance of moderate to severe glabellar lines in adult participants. Glabellar lines are wrinkle-like lines that appear between the eyebrows and can become more noticeable with age or repeated facial expressions. They may affect a person's appearance and confidence.
In this study, all participants will receive a single injection of either IPN10200 or placebo (the study drug). There will be 3 periods in this study:
* A screening period (up to 20 days) to assess whether the participant can take part, requiring at least 1 visit to the study centre.
* A treatment period (Day 1) where all the eligible participants will receive a single injection of IPN10200 or placebo.
* A follow-up period (52 weeks) where participants' health will be monitored, consisting of regular visits to the study centre and 1 telephone call visit.
Participants will undergo health measurements and observation, including blood sampling, physical examinations, clinical evaluations and electrocardiograms (ECG: recording of the electrical activity of heart). They will also be asked to fill in questionnaires and keep a diary. Each participant will be in this study for up to 55 weeks. Participants may withdraw consent to participate at any time.

开始日期2026-02-27

申办/合作机构

Ipsen SA

NCT07435428

/ Recruiting临床3期

A Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled and Open-label Study to Evaluate the Efficacy and Safety of a Single Dose of IPN10200 in the Improvement of Moderate to Severe Glabellar Lines in Adult Participants, and to Evaluate the Long-term Efficacy and Safety of Repeat Doses of IPN10200 in the Same Indication

The purpose of this study is to assess the effectiveness and safety of a single dose of IPN10200 compared to placebo (double-blind phase) and how well and safely repeat doses of IPN10200 work over time (open-label phase) in adult participants with moderate to severe glabellar lines. Glabellar lines are wrinkle-like lines that appear between the eyebrows and can become more noticeable with age or repeated facial expressions. They may affect a person's appearance and confidence.
All participants in the double-blind phase will receive IPN10200 or placebo during the first treatment cycle. De novo participants in the open-label phase will receive IPN10200 during the first treatment cycle. Some participants may receive additional treatment cycles with IPN10200 depending on their eligibility.
There will be 3 periods in this study:
* A screening period (up to 20 days) to assess whether the participant can take part, requiring at least 1 visit to the study centre.
* A treatment period where participants may receive up to 4 treatment cycles. In the double-blind phase, participants receive a single treatment of IPN10200 or placebo. In the open-label phase (rollover participants from double-blind), eligible participants may receive additional cycles of IPN10200. In the open-label phase (de novo participants), participants will receive IPN10200 in the first cycle and eligible participants may receive additional cycles of IPN10200. Requires multiple visits during the first month followed by 1 visit every month.
* A follow-up period (24 weeks) after the last injection where participants' health will be monitored.
Participants will undergo health measurements and observation, including blood sampling, physical examinations, clinical evaluations and electrocardiograms (ECG: recording of the electrical activity of heart). They will also be asked to fill in questionnaires and keep a diary.
Each participant will be in this study for up to 107 weeks. Participants may withdraw consent to participate at any time.

开始日期2026-02-18

申办/合作机构

Ipsen SA

IRCT20100817004582N10

/ Recruiting临床2/3期IIT

Evaluation of the efficacy of botulinum neurotoxin type A (BoNT-A) in the treatment of erectile dysfunction resistant to phosphodiesterase type 5 inhibitors (PDE5Is): a randomized double-blind clinical trial

开始日期2025-10-11

申办/合作机构-

100 项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的临床结果

登录后查看更多信息

100 项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的转化医学

登录后查看更多信息

100 项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的专利（医药）

登录后查看更多信息

1,712

项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的文献（医药）

2026-03-05·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Efficacy of Abobotulinumtoxin A (Dysport) in stump preparation for prosthetic fitting in patients with combat-related limb amputations

Article

作者: Shakhunova, E.B. ; Kasatkina, M.E. ; Ziteva, O.O. ; Ponomarenko, Yu.N. ; Kuznetsova, T.V.

Objective. To evaluate the efficacy of abobotulinumtoxinA in stump preparation for prosthetic fitting in patients with limb amputations. Material and methods. This prospective open-label study included 88 male patients over 18 years old with lower limb amputations due to mine-blast trauma and phantom limb pain syndrome (PLP) with pain intensity of at least 5 points on the visual analogue scale (VAS), absence of significant effect from pharmacological therapy, stump tenderness, and preserved active movements in the transected muscles. AbobotulinumtoxinA at doses of 500—800 U was used to reduce PLP severity. Examination of all patients included collection of complaints and medical history, neurological examination (including manual muscle testing and muscle tone assessment), pain assessment by VAS, psycho-emotional status assessment using the Hospital Anxiety and Depression Scale (HADS), neuropathic pain assessment using the DN4 questionnaire, and stump ultrasound to assess muscle functional status (presence or absence of movements). The total observation period was 21 days. Seven patients with preserved muscles were additionally examined 3 months after botulinum toxin injection. Results. Baseline VAS pain score was 5.8±0.4 points. Clinically significant anxiety according to HADS was present in 86 patients. The mean anxiety score before botulinum toxin injection in the group was 9.1±1.2 points. Depression scores on the HADS were subclinical in all patients, with a mean of 5.3±1.6 points. The mean DN4 neuropathic pain score was 5.9±0.5 points. Pain intensity decreased in all patients, reaching a mean of 3.7±0.5 points on VAS by day 7 after botulinum toxin therapy (p<0.05). By day 14, pain syndrome was completely resolved in all patients. The mean DN4 score was 5.1±0.4 points on day 7 and 2.6±0.9 points on day 14 after injection (p<0.05). Conclusions. Early botulinum toxin therapy enables rapid stump preparation for prosthesis fitting, resolves pain syndrome and accelerates patient rehabilitation.

2026-03-01·Journal of Cosmetic Dermatology

Objective Assessment of the Onset of RelabotulinumtoxinA in the Elevation of the Eyebrow and Its Clinical Implications

Article

作者: Tretti‐Clementoni, Matteo ; De Santis, Andrea ; Di Gregorio, Carlo ; Innocenti, Alessandro ; Leone, Lucia ; Picaut, Philippe ; Iozzo, Ivano ; Belmontesi, Magda

ABSTRACT:

Background:

The new ready‐to‐use botulinum toxins effectively treat lateral canthal lines; there is still little data on their efficacy in treating glabellar lines. The combined treatment of lateral canthal and glabellar lines allows the eyebrow to be repositioned.

Aims:

To show the onset and action of RelabotulinumtoxinA on the periocular area, by measuring the variations of the area under the eyebrow in a real‐life setting.

Patients/Methods:

In this real‐life, multi‐center case series, 36 patients (30 women, 6 men), aged 30–62 years, were treated with RelabotulinumtoxinA in glabellar and lateral canthal areas; patients were treated on day 0 (T0) and followed until day 30. Photos taken at T0 and at all follow‐up time points were compared in calculating the median of the palpebral surface.

Results:

All patients responded to the treatment. Most of RelabotulinumtoxinA's effect on eyebrow position (76.25%) was seen within day 2, peaking in the first 24 h. The variation rate sharply declines by day 7. Patients showed a median increase in the exposed eyelid area of +11.91% compared to T0.

Conclusions:

In the real‐world setting, RelabotulinumtoxinA showed efficacy in treating GLs and LCLs. In the post‐intervention phases (follow‐up and potential touch‐ups), the fast onset of the ready‐to‐use product can save time. The palpebral area measurement technique, which was selected to assess objectively the response, may allow for a higher level of precision than measuring distances in the periocular range and can be helpful in this type of study.

2026-03-01·BIOMATERIALS

DETOX: An innovative dendritic nanosystem for the delivery of BoNT/A LC domain to ischemic neurons

Article

作者: Santos, Sofia D ; Furihata, Tomomi ; Fonseca, Fátima ; Magalhães, Natália ; Moreira, Débora A ; Leiro, Victoria ; Silva, Duarte ; Torrado, Marília ; Piantino, Marie ; Matsusaki, Michiya ; Sinthon, Clara ; Ferreira-da-Silva, Frederico ; Pêgo, Ana P

Ischemic stroke is a leading cause of mortality and morbidity worldwide. Nevertheless, current treatments are very ineffective as they only restore the blood flow, lacking neuroprotective properties. Excitotoxicity, primarily mediated by the overaccumulation of glutamate in the synaptic space, plays a key role in infarct expansion. Therefore, we propose a novel neuroprotective strategy to limit excessive glutamate release using the light-chain (LC) of Botulinum neurotoxin type A (BoNT/A), known to block neurotransmitters exocytosis, transported and delivered with proprietary fully biodegradable PEG-dendritic block copolymers (fbB). Here, the synthesis of 'taggable' dendrimers at their PEG end was further explored, where a Cy5.5 molecule was tagged through this point to allow for the tracking of nanoparticles in complex biological systems. A highly pure and catalytically active LC protein was produced and successfully complexed with the fbB dendrimers, forming DETOX nanoparticles. These systems, with nanosizes and mildly positive net charges, achieved up to 84 % LC-loading efficiency. DETOX significantly enhanced the cleavage of SNAP-25 - the LC's target - in neurons compared to BoNT/A and demonstrated a faster onset of action than the full-length neurotoxin, without inducing cytotoxicity. Importantly, DETOX capacity to reduce glutamate exocytosis was demonstrated in an in vitro model of ischemia. Moreover, DETOX nanoparticles showed their remarkable ability to permeate a 3D full-human blood-brain barrier model, indicating their promising application in humans. These findings position DETOX nanosystems as a groundbreaking neuroprotective strategy, offering a novel, clinically relevant approach for mitigating excitotoxicity in ischemic stroke, paving the way for advanced CNS therapeutics.

113

项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的新闻（医药）

2026-03-27

·医药专利

全球首创！誉颜制药重组A型肉毒毒素"芮妥欣®"获批上市

中国生物医药产业迈入"重组肉毒毒素治疗新时代" 【重庆，2026年3月27日】重庆誉颜制药有限公司（以下简称"誉颜制药"）今日宣布，其自主研发的全球首款重组A型肉毒毒素注射剂——芮妥欣®（Retoxin®，项目代号：YY001）正式获得国家药品监督管理局（NMPA）批准上市，用于改善成人中度至重度眉间纹。这一里程碑事件标志着全球肉毒毒素产业正式从"天然提取时代"迈入"基因重组时代"，中国生物医药企业在该领域实现从跟跑到领跑的历史性跨越。一、技术突破：从天然提取到精准重组的范式革命肉毒毒素（Botulinum Toxin）作为自然界毒性最强的蛋白质之一，自1989年首次获批用于医疗以来，其生产长期依赖肉毒杆菌（Clostridium botulinum）发酵提取。传统制备工艺存在生物安全风险高、批次一致性难控、纯度受限等固有缺陷。誉颜制药依托自主创建的系列化重组蛋白药物研发平台，通过基因工程技术在体外表达系统中精准合成肉毒毒素，实现了三大技术突破：技术维度传统提取工艺重组技术路线（YY001）安全性依赖致病性细菌发酵，存在生物安全隐患规避病原菌管控风险，无水平基因转移风险纯度通常90-95%，含复杂杂质谱纯度高达99%以上批次一致性受发酵条件影响，批间差异较大基因工程生产，批次均一性达医疗级标准免疫原性杂质蛋白可能引发免疫反应免疫原性显著降低，过敏风险更小誉颜制药首席科学官杨武博士表示："重组A型肉毒毒素的成功获批是誉颜制药顺利进入商业化发展的第一步。在自研创建的重组技术平台上，公司研发团队正同步开发系列肉毒毒素创新产品，旨在覆盖更多神经系统疾病及其他适应症，构建一条从产品研发、生产转化到临床应用的完整生态链。"二、临床布局：从医美向严肃医疗的适应症拓展此次获批的眉间纹适应症仅是YY001商业化征程的起点。誉颜制药已前瞻性地布局医疗领域，目前该产品在治疗成人上肢肌肉痉挛的临床应用探索持续深入——在中国已成功完成II期临床试验，目前正在推进III期临床试验。这一"医美+医疗"双轮驱动战略，与全球肉毒毒素市场的发展趋势高度契合。据统计，全球已获批的肉毒毒素适应症超过20种，涵盖慢性偏头痛、肌张力障碍、膀胱过度活动症、多汗症等治疗领域，医疗用途市场占比持续提升。三、全球视野：重组肉毒毒素研发格局与中国力量 YY001的获批上市，使誉颜制药成为全球首家实现重组A型肉毒毒素商业化落地的企业。在此之前，全球范围内尚无重组技术路线的肉毒毒素产品获批，所有上市产品均基于传统细菌发酵提取工艺。全球重组肉毒毒素研发格局（截至2026年3月）企业/机构技术路线研发阶段核心特点誉颜制药（中国）重组A型已获批上市全球首款，纯度>99%若弋生物（中国）昆虫细胞重组 III期临床全球唯一昆虫细胞制备，安全窗口增加3倍新诺贝生物（中国）合成生物学+AI 临床前 AI蛋白设计，免疫原性降低60%以上Revelyx Bio（美国）重组液体剂型 A轮融资全球首款液体剂型，免复溶华东医药（中国）引进YY001 商业化阶段 2023年引进，差异化布局从研发格局可见，中国已成为全球重组肉毒毒素创新的核心策源地。除誉颜制药率先撞线外，若弋生物的第三代重组产品已进入III期临床，其通过昆虫细胞制备技术实现"药效延长100%、安全窗口增加3倍"的突破性进展；新诺贝生物则依托合成生物学与AI技术，构建绿色制备工艺。君合盟生物跟的最紧。四、市场洞察：百亿赛道迎来结构性变革机遇全球市场规模根据Fortune Business Insights数据，2025年全球肉毒毒素市场规模达119.4亿美元，预计2026年将增至128.4亿美元，2034年有望突破200亿美元，年复合增长率（CAGR）约14.1%。北美目前占据最大市场份额，但亚太地区是增长最快的市场，2025年规模达24.9亿美元，预计2026年将达26.8亿美元。中国市场潜力弗若斯特沙利文预测，中国肉毒毒素市场规模将于2025年及2030年分别达到126亿元及390亿元，近五年复合增长率达30%。目前中国市场仍以进口产品为主导，但随着国产重组产品的技术突破和获批上市，市场格局正迎来深刻变革：价格可及性提升：重组技术的高生产效率、低成本优势，有望推动产品价格更加亲民供给端扩容：从您提供的CDE受理数据来看，目前国内已有7家企业布局重组A型肉毒毒素，申报总数达18个，君合盟生物（6个）、誉颜制药（4个）位居前列适应症拓展：从医美向神经系统疾病、疼痛管理等严肃医疗领域延伸竞争格局演变当前中国肉毒毒素市场呈现"外资主导、国产崛起"态势：进口产品：艾尔建（Botox®）、Ipsen（Dysport®）、Merz（Xeomin®）、Hugel（Letybo®）等国产产品：兰州生物（衡力®）、爱美客（代理韩国Hutox，2026年1月获批） YY001作为全球首款重组产品，以技术代差优势切入市场，有望打破"国产=低端"的固有认知，重塑高端肉毒毒素市场竞争格局。五、产业意义：开启重组肉毒毒素治疗新时代誉颜制药董事长兼CEO刘淼先生表示："非常高兴看到重组A型肉毒毒素在中国的获批，这是全球范围内被批准上市的第一款重组A型肉毒毒素。公司将以此为新起点，秉持科学精神和高效运营，深耕神经毒素领域，以重组技术平台为核心驱动，打造覆盖更多适应症的产品管线，为全球临床医生和患者源源不断地提供源自中国的治疗方案，开启重组肉毒毒素治疗的新时代。" YY001的获批具有三重里程碑意义：技术层面：验证了重组技术路线在肉毒毒素领域的可行性，为行业技术迭代树立标杆产业层面：推动全球肉毒毒素产业从"1.0时代"（天然提取）向"3.0时代"（重组工程化）跨越战略层面：彰显中国生物医药企业在高端生物制剂领域的原始创新能力，为"中国方案"走向全球奠定基础关于誉颜制药誉颜制药专注于重组技术路线的肉毒毒素研发、生产与商业化。公司汇聚了国际优秀的肉毒毒素基础研究专家及拥有丰富行业经验的资深美、中学者，组建了一支兼具前沿科学视野与产业化能力的核心团队。依托自主创建的系列化重组蛋白药物研发平台，誉颜制药成功研发出全球首款重组A型肉毒毒素，实现了该领域从天然提取到精准基因重组的技术突破。

上市批准

2026-03-27

·医美部落

誉颜制药 | 全球首款「重组A型」肉毒素「芮妥欣®」获批上市

在医学领域中，创新技术在不断更新进展，求美者愈发关注那些能够显著改善人类生活质量的创新药物。特别是在医美非外科手术处理类方面，肉毒毒素因其在减少皱纹和改善皮肤外观方面的显著效果而广受欢迎。随着对肉毒素安全性和有效性的不断研究，被广泛应用于多个美容项目当中。 2026年3月25日，重庆誉颜制药自主研发的芮妥欣®Retoxin®"注射用重组A型肉毒毒素"正式获国家药监局批准，注册证号：国药准字S20260019，产品主要用于改善成人中度至重度眉间纹，成为全球首款获批的重组A型肉毒素产品。 # 01 全球首款重组A型肉毒毒素重组A型肉毒毒素YY001是由重庆誉颜制药有限公司自主研发的，并且拥有全球知识产权。YY001在保持蛋白活性的同时，巧妙地规避了传统肉毒杆菌生产方法所带来的生物安全风险，具有纯度高、比活性高、免疫原性低的特征，被业内视为新一代肉毒毒素。在医美应用的基础上，YY001用于治疗成人上肢肌肉痉挛的临床研究（代号YY001-002）也于2024年7月在中国进入II期临床试验阶段，在全球范围内首先将重组A型肉毒毒素应用于医疗领域。YY001在大规模人群的III期临床研究结果显示，其有效性、安全性和免疫原性都达到了既定的临床试验终点，与对照药相比表现优异。 # 02 肉毒素是医美刚需在轻医美领域，肉毒素产品无疑是主流或是核心产品，其市场潜力巨大，且持续受到行业内外的广泛关注。截止目前，国内共有7款A型肉毒素产品的获批上市，分别是美国艾尔建的Botox®保妥适、兰州生物的衡力®、法国Ipsen的Dysport®吉适、韩国Hugel的Letybo®乐提葆、德国Merz的Xeomin®思奥美、美国Revance的Daxxify®达希斐和韩国Hutox®解锁橙。这些产品各具特色，满足了不同消费者的需求，共同推动了医美市场的发展。在重组A型肉毒素这一细分领域，国内的竞争同样激烈。国内除了誉颜制药之外，还有包括君合盟、迪新宸科、若弋生物、耀海诺信等都有布局，其中，君合盟的重组A型肉毒素于2023年12月获批“用于成人中重度眉间纹”适应症的临床试验，目前即将进入III期临床阶段；迪新宸科的重组A型肉毒素DN001于2024年8月获批准开展临床，适应症也为“中重度眉间纹”。 # 03 签约华东医药在2023年11月14日，华东医药旗下全资子公司欣可丽美学、杭州产业投资有限公司、杭州拱墅国投产业发展有限公司与重庆誉颜制药有限公司及其股东代表签署股权投资协议。与此同时，华东医药与重庆誉颜签署了注射用重组A型肉毒毒素YY001独家经销协议，双方建立了战略合作伙伴关系。根据独家经销协议条款，华东医药获得重庆誉颜拥有的重组A型肉毒素YY001产品在中国大陆、香港特别行政区、澳门特别行政区医美适应症领域的独家商业化权益。 # 04 关于誉颜制药誉颜制药是一家由广州因明生物控股的创新驱动型生物制药企业，专注于重组技术路线的肉毒毒素研发、生产与商业化，汇聚了国际优秀的肉毒毒素基础研究专家及拥有丰富行业经验的资深美、中学者，组建了一支兼具前沿科学视野与产业化能力的核心团队。公司拥有由肉毒毒素基础研究领域国际知名科学家及肉毒毒素药物研发资深旅美华裔学者组建的科研团队，创建了系列化重组蛋白药物研发平台，成功研发出全球首个重组A型肉毒毒素。此外，誉颜制药作为全球首家完成重组A型肉毒毒素获批的创新药企，其用于治疗成人上肢肌肉痉挛的适应症也成功完成II期临床试验，目前正在推进III期临床试验。

2026-03-18

·合成生物学网

首创昆虫细胞重组肉毒素！若弋生物融资超亿元！

（合成生物学网）2026年3月14日，苏州若弋生物科技有限公司成功完成数千万元A轮融资，本轮投资由昆玉人才基金骐骥共进共同投资。本轮融资款将主要用于重组蛋白药物的AI设计平台和先进制造平台的建设。截至目前，若弋生物已经完成了六轮融资，累计金额超亿元。若弋生物是专注重组蛋白药物研发的高新技术企业，已构建三大核心技术体系，打造 9 项独家及领先技术平台，研发管线覆盖医美抗衰、神经疾病治疗等领域，多项成果已获监管批件及新适应症 IND 受理。公司核心管线CB2201为第三代重组 A 型肉毒毒素，已于 2025 年获得 IND 批准。该产品严格保留 100% 天然 A 型肉毒素氨基酸序列，保障临床可比性；同时通过制剂优化实现关键突破：作用时长较主流竞品延长 1 倍、安全窗提升 3 倍、药物弥散性显著降低。作为全球首个采用昆虫细胞制备的重组 A 型肉毒毒素，CB2201 从生产源头规避传统细菌表达体系的生物安全风险，经工艺优化后纯度突破 99%，无外源标签、无序列 / 结构异构体，安全性与稳定性大幅提升。在底层技术上，若弋生物攻克行业痛点，自主研发Sf9 昆虫细胞 - 杆状病毒表达体系 2.0，解决内源性病毒污染、蛋白传代稳定性不足等难题；同时实现蛋白表达产量显著提升与无血清培养基国产替代，降低生产成本、保障供应链自主可控。该平台可靠性已通过临床 I 期试验验证。临床进展方面，CB2201 针对中重度眉间纹适应症的 II 期临床试验，已于 2026 年 1 月在北京大学第一医院完成首例入组，由吴艳教授担任主要研究者。国内肉毒毒素市场已获批 6 款产品，分别为国产的衡力®与进口的Botox®（保妥适）、Dysport®（吉适）、Letybo®（乐提葆）、Xeomin®（思奥美）、Daxxify®（达希斐）。呈现 “进口主导、国产追赶” 格局。若弋生物在第三代重组肉毒素基础上，已布局第四代管线，包括锌指蛋白递送工程化肉毒素、AI 辅助蛋白改造、新型血清型肉毒素等，部分管线完成原理验证并进入 CMC 阶段，技术布局保持行业领先。本轮融资将进一步强化若弋生物在重组蛋白药物领域的研发与制造能力，推动核心产品临床转化与商业化落地，助力国产重组蛋白药物创新升级。

临床申请

100 项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09764	A型肉毒杆菌毒素（Ipsen Biopharm Ltd）	M03AX01	DB00083

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肌肉痉挛	美国	Ipsen Biopharm Ltd.	2017-06-14
上下肢痉挛	美国	Ipsen Biopharm Ltd.	2016-07-29
眉间纹	美国	Ipsen Biopharm Ltd.	2009-04-29
斜颈	美国	Ipsen Biopharm Ltd.	2009-04-29
肌张力失调	奥地利	Ipsen SA	2009-01-28
肌张力失调	比利时	Ipsen SA	2009-01-28
肌张力失调	保加利亚	Ipsen SA	2009-01-28
肌张力失调	克罗地亚	Ipsen SA	2009-01-28
肌张力失调	塞浦路斯	Ipsen SA	2009-01-28
肌张力失调	捷克	Ipsen SA	2009-01-28
肌张力失调	丹麦	Ipsen SA	2009-01-28
肌张力失调	爱沙尼亚	Ipsen SA	2009-01-28
肌张力失调	芬兰	Ipsen SA	2009-01-28
肌张力失调	法国	Ipsen SA	2009-01-28
肌张力失调	德国	Ipsen SA	2009-01-28
肌张力失调	希腊	Ipsen SA	2009-01-28
肌张力失调	匈牙利	Ipsen SA	2009-01-28
肌张力失调	冰岛	Ipsen SA	2009-01-28
肌张力失调	爱尔兰	Ipsen SA	2009-01-28
肌张力失调	意大利	Ipsen SA	2009-01-28

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
偏头痛	临床3期	意大利	Ipsen SA	2023-10-12
偏头痛	临床3期	英国	Ipsen SA	2023-10-12
先兆偏头痛	临床3期	美国	Ipsen SA	2023-09-29
先兆偏头痛	临床3期	加拿大	Ipsen SA	2023-09-29
先兆偏头痛	临床3期	捷克	Ipsen SA	2023-09-29
先兆偏头痛	临床3期	法国	Ipsen SA	2023-09-29
先兆偏头痛	临床3期	德国	Ipsen SA	2023-09-29
先兆偏头痛	临床3期	波兰	Ipsen SA	2023-09-29
先兆偏头痛	临床3期	西班牙	Ipsen SA	2023-09-29
无先兆偏头痛	临床3期	美国	Ipsen SA	2023-09-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05167864 (JBDX, CTgov)	N/A	-	143	Onabotulinumtoxina for Injection (OnabotulinumtoxinA)	糧範構築鏇簾廠膚淵鹽(夢夢淵膚積遞壓鏇鏇鑰) = 製憲鏇鬱齋鹽淵簾齋蓋簾壓遞築醖築餘範鹹鏇 (窪鬱鹹壓餘觸廠網簾範, 5.0) 更多	-	2025-01-17
				Abobotulinumtoxina for Injection (AbobotulinumtoxinA)	糧範構築鏇簾廠膚淵鹽(夢夢淵膚積遞壓鏇鏇鑰) = 願壓網襯膚繭蓋夢構衊簾壓遞築醖築餘範鹹鏇 (窪鬱鹹壓餘觸廠網簾範, 5.2) 更多
NCT05277337 (STAR \| Phase IV study, CTgov)	临床4期	眉间纹	150	Alluzience (Group 1 (Alluzience))	膚淵網網憲廠齋構願顧(獵廠齋鏇構製顧築艱憲) = 膚憲壓餘衊願糧襯鏇網鹽艱膚鏇壓構遞積餘遞 (鑰廠繭蓋鏇壓鏇鏇築選, 0.414) 更多	-	2024-02-16
				BoNT-A+Vistabel (Group 2 (Powder BoNT-A: BOTOX/Vistabel))	膚淵網網憲廠齋構願顧(獵廠齋鏇構製顧築艱憲) = 顧襯衊糧鑰鬱範築餘築鹽艱膚鏇壓構遞積餘遞 (鑰廠繭蓋鏇壓鏇鏇築選, 0.831) 更多
NCT03543254 (CTgov)	临床2期	偏头痛 \| 慢性病	20	BoNT-A	遞觸襯簾艱製襯選範鏇 = 艱顧願觸範積蓋繭構顧鑰餘繭繭齋鑰選廠構壓 (窪選選艱餘顧積壓夢選, 獵顧餘網艱遞艱鹽遞鹽 ~ 網衊顧醖選簾繭築膚齋) 更多	-	2024-01-30
NCT03469999 (CTgov)	临床3期	脑瘫	12	Dysport	窪選淵膚繭積網窪膚選(遞鑰鏇觸繭顧壓壓餘遞) = 願夢襯艱範遞夢鬱觸壓製窪鑰獵廠獵鑰鹹觸襯 (築選選衊憲壓襯窪餘夢, 膚襯鬱憲膚構襯顧衊襯 ~ 淵憲繭築鹽鑰窪衊築顧) 更多	-	2022-06-01
NCT01459666 (CTgov)	临床4期	瘢痕 \| 额头皱纹 \| 皮肤肿瘤 ... 更多	9	Dysport (Dysport (abobotulinumtoxinA))	遞憲遞遞憲襯艱網獵餘(醖鬱糧醖鏇鏇鹽廠夢顧) = 構遞壓齋壓製鹽齋積蓋夢壓選觸壓糧夢艱遞鹹 (遞鹹憲膚鹹願選糧鏇範, 構鹹鏇簾觸廠醖齋淵夢 ~ 糧憲鑰膚壓襯膚顧選積) 更多	-	2022-05-26
				Bacteriostatic 0.9% Sodium Chloride (vehicle) (Placebo)	遞憲遞遞憲襯艱網獵餘(醖鬱糧醖鏇鏇鹽廠夢顧) = 觸淵襯蓋觸觸構鹽醖網夢壓選觸壓糧夢艱遞鹹 (遞鹹憲膚鹹願選糧鏇範, 網網襯淵窪製淵淵衊衊 ~ 顧構積窪窪願願鏇選艱) 更多
NCT02660138 (CONTENT1, CTgov)	临床3期	尿失禁 \| 神经源性逼尿肌过度活动 \| 脊髓损伤 ... 更多	227	placebo (Placebo)	鹹醖積簾選憲膚簾淵觸(選糧獵壓淵築鬱憲壓鏇) = 顧鑰繭膚鏇鏇遞範願廠夢鏇窪顧憲襯獵遞簾糧 (窪繭淵廠淵簾選糧簾襯, 2.01) 更多	-	2021-06-16
				Dysport (Dysport® 600 U)	鹹醖積簾選憲膚簾淵觸(選糧獵壓淵築鬱憲壓鏇) = 餘遞餘蓋繭範鏇壓顧構夢鏇窪顧憲襯獵遞簾糧 (窪繭淵廠淵簾選糧簾襯, 2.04) 更多
NCT03736928 (CTgov)	临床2期	眉间纹	401	placebo	顧蓋繭鹽選齋鑰遞壓衊 = 膚蓋膚築衊築繭淵蓋製繭憲窪糧廠壓繭遞願壓 (鬱憲遞窪醖鬱鹽膚艱願, 廠築遞壓繭網簾構構餘 ~ 遞選簾簾鏇範鹹糧艱憲) 更多	-	2021-02-11
NCT04080882 (CTgov)	临床2期	-	80	Placebo (Placebo)	構鏇夢範構膚蓋願觸網 = 膚襯鹽鬱願觸糧網築構製積選鏇範製艱襯壓壓 (觸窪壓簾襯鬱鏇淵鏇顧, 糧觸憲憲蓋壓艱顧範願 ~ 醖膚鏇壓顧廠構廠艱網) 更多	-	2021-01-22
				AbobotulinumtoxinA dose 1 (AbobotulinumtoxinA Dose 1)	構鏇夢範構膚蓋願觸網 = 選糧遞廠範膚鬱襯夢窪製積選鏇範製艱襯壓壓 (觸窪壓簾襯鬱鏇淵鏇顧, 鬱獵積壓艱鏇衊築積構 ~ 糧憲廠築膚鬱夢築繭窪) 更多
AAN2020	N/A	肌张力失调	43	OnabotulinumToxinA	選積觸鏇窪窪鑰餘襯積(壓淵獵廠襯鹹淵窪選願) = 憲繭齋繭壓獵壓淵構夢糧鏇遞遞醖齋餘齋構範 (構壓壓醖繭醖觸遞糧蓋 ) 更多	-	2020-04-14
AAN2020	N/A	肌肉痉挛一线	210	Oral antispastic medications	範積簾窪鬱鹽淵鏇醖願(淵鏇構淵願繭鏇窪壓鬱) = 艱膚鬱鏇夢醖鏇艱範廠鑰廠廠鹽鏇築衊蓋遞餘 (淵糧糧範蓋鹽觸艱醖鹹 )	-	2020-04-14
				Home physiotherapy	壓願簾憲夢壓繭鹽範鏇(積蓋壓廠糧衊觸築餘憲) = 選壓鏇膚構窪憲網鏇鏇築鏇鏇鏇構遞網鏇製壓 (遞鹽積鹽衊選膚壓觸鏇 )